Guardian Therapeutics

Bringing to life the full potential of aptamer therapeutics.

Aptamers

  • Aptamers are short nucleic acids that fold into distinct tertiary structures in order to recognize specific target molecules
  • At the molecular level, aptamers bind to their target site through electrostatic and hydrophobic interactions as well as complementary shapes
  • High affinity (KD = pM-nM)
  • Aptamers have been discovered that are specific to small molecules, proteins, nucleic acids, cells, tissues and organisms
  • Aptamers have the ability to disrupt protein:protein interactions and produce therapeutic effects

BT200 aptamer:vWF A1 domain complex

...

Therapeutic Areas & Programs

We focus on four different therapeutic areas and programs, each with their own targets.

Hematology
Hematology
Oncology ADC
Oncology ApDC
Immuno-Oncology
Immuno-Oncology
Gastrointestinal
Gastrointestinal

Revolutionizing Discovery Of Aptamer Therapeutics


Rapid Aptamer Discovery Process

Deep Sequencing

Therapeutic-relevant Nucleotide Chemistries

High-throughput Aptamer Synthesis

home-discovery-aptamer

ApDC

Aptamer Drug Conjugates: A Novel Targeted Delivery Platform for Oncology

...

Targeted therapy modality in which aptamers replace mAbs in drug conjugates

ApDC payload can be tailored to suit therapeutic strategy

ApDCs offer significant CMC advantages over ADC

Our People

Meet the leaders who are innovating Aptamer Therapeutics

Team Graphic

Contact

© 2022 Guardian Therapeutics. All rights reserved.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com